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Abstract : Accumulated cellular defects over time and a decline in immune function are hallmarks of aging. Since
the principal role of the immune system is to protect the host from infections and illness, defects in immune functions
increase the susceptibility to and severity of infection or cancer, decreasing quality of life. Compared to the extensive
studies of age-associated changes to the adaptive immune system, alterations to the innate immune system with
advanced age are not well documented. Aging affects every aspect of innate immunity, including alterations in cel-
lular composition, cell number, phenotype and function, and these alterations may significantly contribute to impair-
ments in the adaptive immune system. Understanding the underlying mechanism of immune aging will allow the
development of preventive or therapeutic strategies to restore age-associated immune defects that are beneficial for
the elderly and that may dramatically enhance their qualities of life. Recent advances in potential therapeutic options
for immunity restoration in the aging innate immune system are discussed.
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1. Introduction
Improved sanitation, development of preventive and
therapeutic vaccines, development of effective antibiotics, and
advances in medical technologies greatly increase human life
expectancy and contribute to the increased aged population.
This, however, became a significant concern for the global
public healthcare system, as a doubling of the aged population
(age over 65 years) is predicted in the next 20 years (Fig 1). In
2004, the aged population accounted for 12% of the total US
population but consumed more than 30% of the healthcare
expenditures.1 This rapid and inevitable population aging has
serious impacts on both the economy and the healthcare
system. 
Aging is accompanied by a decline in immune functions,
referred to as immune aging or immune senescence. In addition,
life-long exposure to environmental factors and countless
interactions with infectious agents lead to chronic inflammatory
states in older individuals, known as inflammaging, which is
characterized by increased proinflammatory mediators in the
serum.2 Due to a decline in immune function, the elderly suffer
more frequently and more severely from infectious agents than
do younger people.3 In addition, the elderly respond poorly to
the same preventive vaccines to infectious agents compared to the
responses in young people. Cancer incidence and autoimmune
disorders are also known to be increased with age.4 Although the
causes for these events are complex, it is evident that immunity
plays a key role in the health of the elderly, as disease
susceptibility significantly depends on immune function. Aging
is clearly associated with defects in both the innate and adaptive
immune systems. While immune aging in the adaptive immune
system is relatively well-documented,5,6 the innate immune
system is less well understood. This study attempts to address
the current knowledge on age-associated changes in innate
immunity and potential interventions that may restore or
rejuvenate an aged immune system. 
2. Aging and Hematopoiesis
Cells of the immune system have limited life spans and a
small reserve of hematopoietic stem cells (HSCs) in the bone
marrow to continuously replenish them throughout a lifetime.7
Bone marrow contains HSCs and stromal non-hematopoietic
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stem cells that provide a microenvironment (niche) for
hematopoiesis. Although HSC compartments are not exempt
from aging, little is known about the effects of aging on HSC
compartments or the effects of aged HSC on the downstream
function of the immune system. 
The hematopoietic compartment of bone marrow is known to
decrease with age, accompanied by replacement with adipose
tissue.8 Disturbances in the cytokine and hormonal milieu
(systemic environment) substantially affect both HSCs and non-
hematopoietic stroma and contribute to the age-dependent
changes in bone marrow that lead to alterations in hematopoiesis.
In line with this, treatment of aged mice with recombinant
growth hormones significantly enhanced the cellularity with
decreased adiposity of bone marrow,9 implying that (1) HSCs
retain much of their intrinsic regenerative potential with age
and (2) the systemic environment and the niche in which the
HSCs reside limit their full potential with advancing age. Serial
murine bone marrow transplantation experiments demonstrated
that HSCs from young and old mice are indistinguishable in
their progenitor activities,10 implying that stem cell exhaustion
does not accompany normal aging. However, another study
showed that there are quantitative differences in HSC activity
with aging.11 Limiting dilution assays of HSCs from old and
young mice revealed that their progenitor activities in vivo were
indistinguishable; HSCs contents were five times higher in the
bone marrow of old mice, with significantly reduced bone
marrow homing and repopulation efficiency. Furthermore, HSCs
of aged mice exhibited an increased propensity toward myeloid
lineage differentiation compared to that of lymphoid lineage
differentiation, possibly contributing to decline in lymphopoiesis
with aging.12,13 This is in part due to the decrease in IL-7
production by bone marrow stromal cells14, an essential
cytokine for lymphopoiesis, further supporting the notion that
systemic and local environments limit HSC potential. These
data suggest that the abilities of HSCs and bone marrow stroma
to nurture hematopoiesis are substantially altered during aging.
In addition, genetic studies in murine models15,16 showed that
aged HSCs differ from their younger counterparts. The global
gene expression profile revealed coordinated changes in
lineage-specification genes and chromatin remodeling genes.
Since all cells of the immune system are derived from HSCs,
age-associated changes in HSC compartments greatly affect the
innate and adaptive arms of the immune system. An
understanding of the overall impacts of aging on hematopoiesis
and its microenvironment is of clinical relevance, particularly
in cell therapy settings, including bone marrow or HSC
transplantation.
3. Age-Associated Alterations in
Innate Immune Cells
Clinical studies have shown that the ability of the elderly to
respond to infection is greatly diminished compared to that in
younger populations. A decline in function of the innate
immune system with advanced age17 is implicated as the
primary cause of this problem (Fig 2).
3.1 Polymorphonuclear Cells
Polymorphonuclear cells (PMNs) are one of the key effector
cells in the innate immune response against microbial infection
and injury and are thus indispensible for host defense. They are
quickly recruited to the sites of infection in response to tissue
damage, complement activation or microbial products and
participate in the removal of pathogens via phagocytosis of
opsonized particles or production of bacteriostatic and
bacteriocidal products. In addition, these cells influence
adaptive immunity through the production of chemotactic
factors and cytokines. Their capabilities, including chemotactic
migration, adhesion, and phagocytosis, are critical for proper
defense against microbial invasion and injury. Although the
number of circulating neutrophils does not appear to be
significantly affected by aging, there are conflicting results
regarding the functional defects of PMNs in the aged
population both in vitro and in vivo. Wenisch et al.18 reported a
significant reduction of PMN function with increasing age. In
contrast, Niwa et al.19 showed that the function of PMNs in
aged individuals was diminished and there was no significant
difference between people older than 80 years old and the
young volunteers. However, this observation may reflect the
results of selective pressure because only the healthiest people
survived into the aged group. Human PMNs from young and
Figure 1. The total world population, the number of people aged
65 or greater and the proportion of aged population. The figure is
based on statistics from the World Health Organization website. 
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aged populations have displayed compatible capacity for
adhesion and phagocytosis.20 However, a significant decrease
in the bactericidal activity through a reduction in the reactive
oxygen species (ROS) producing capacity21 was noted in the
elderly, suggesting that longer durations are inevitable to
resolve infection in elderly individuals. In addition, aged PMNs
express more proapoptotic proteins and are more prone to
undergo programmed cell death due to their inability to
neutralize reactive oxygen species.20 The lifespan of a PMN is
relatively short (5.4 days in circulation),22 and the enhanced
apoptotic cell death of aged PMNs further decrease their life
spans. This alteration may provide insufficient protection
against pathogens, leading to an increased risk of infection.
Thus, the functions of PMNs are compromised in the aged
population. Although these age-related alterations to PMN
functions can be overcome through compensatory adaptive
immune responses, the changes in the adaptive immune system
in aged individuals further weaken the innate arm, leading to an
increased susceptibility to microbial infections. Thus,
restoration of senescent immunity in aged individuals requires
strategies which repair both the innate and adaptive immune
systems.
3.2 Monocytes/Macrophages
Monocytes originate from myeloid precursors in the bone
marrow and are located both in circulation and within tissues.
They respond to infection and inflammation by differentiating
into antigen presenting cells such as macrophages or dendritic
cells (DCs).23 Thus, monocytes serve as a bridge between
adaptive and innate immunity. They are able to directly remove
pathogens via phagocytosis or through the production of
bacteriostatic and bacteriocidal products which are induced by
components of microorganisms or by cytokines from T cells,
natural killer (NK) cells and DCs. Macrophages also participate
in wound healing by preventing infection and promoting
angiogenesis.24 Although the number of monocytes increases
with age, there are age-dependent decreases in their function.25
Associations with either decreased pathogen receptor (toll-like
receptor, TLR) expression26 or defective TLR-derived signal
transduction27 have been reported in murine models. Studies of
human monocytes have also revealed age-associated declines
in cytokine responses to TLR.28 Macrophages from aged mice
produced less ROS upon stimulation,29 which leads to reduced
bactericidal activity. As a consequence, elderly individuals tend
to require a longer duration to recover from infections and
Figure 2. A model of the contributions of cellular and molecular changes accompanying different components of the immune systems
due to aging to clinical consequences in the aged population. Hematopoietic stem cells give rise to all the cell types of the immune sys-
tem under signals from the systemic and local microenvironments. Age-associated alterations in the functional parameters of innate
immunity, as well as plausible interactions between components of the immune systems are summarized. LTC-IC, long-term culture ini-
tiating cells.
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injuries. In addition, defects in CD80 up-regulation are
observed in monocytes upon TLR engagement30 and have a
significant impact on adaptive immunity, as this molecule is
associated with humoral immunity to viruses. This implies that
defects in monocyte/macrophage function can also contribute
to the alterations seen in other components of the immune
system through soluble factors and cytokines. Observations of
increased proinflammatory molecules in the sera of aged
individuals added an additional layer of complexity to the
interpretation of functional defects in monocyte/macrophage as
these may be associated with inflammaging.31 Macrophages
are considered to be the primary producer of pro-inflammatory
cytokines and may actively contribute to immune aging via
secretion. For example, macrophages of aged mice produce
higher levels of prostaglandin E2 (PGE2), which directly
inhibits T cells and dendritic cell function, compared to those in
their young counterparts.32
3.3 NK Cells
These large granular lymphocytes participate in early defense
against certain malignancies and viral infections either via
direct contact-dependent lysis or indirect antibody dependent
cell-mediated cytotoxicity (ADCC). Several age-related
alterations in NK cells have been described.33 Compared to
young healthy subjects, NK cells from the elderly had lower
proliferation and production rates, which may be associated
with telomere shortening in HSCs. The absolute number of NK
cells increases with age, accompanied by an increase in the
CD56dim mature cytotoxic subpopulation of NK cells.34 While
there was previous controversy over NK cell activity in
peripheral blood lymphocytes, studies using purified NK cells
clarified that cytolytic activity decreases with age.35 Thus, the
diminished NK cell activity during aging may be compensated
for by the increase in NK cell number. In addition to cytolytic
functions in malignant or virus-infected cells, NK cells
modulate cells of the innate and adaptive immune systems
through the production of cytokines. However, defects in
cytokine production by NK cells may compromise the
immunity against viral infections and malignancies.
Additionally, there is a strong correlation between infection risk
and mortality in aged individuals with reduced NK cell
activity.36
3.4 Dendritic Cells
DCs are a heterogeneous population of specialized antigen
presenting cells that constantly sample the surroundings for
pathogens such as viruses and bacteria through pattern
recognizing receptors such as toll-like receptors (TLRs). Their
strategic localization at various portals of pathogen entry and
capacities for uptake, processing, and presentation of antigens
to T cells impart DCs with unique roles in bridging the innate
and adaptive immune systems.37 While various DC subsets
share key functions in the processing and presentation of
antigens to naïve T cells for the induction of adaptive immune
responses, there are considerable differences among the subsets
with regard to phenotype, migratory pattern, tissue localization
and cytokine production. At present, the effects of age on DCs
are still not fully understood. 
Upon contact with pathogens through TLRs, dendritic cells
undergo a maturation process and migrate to the lymph nodes,
where they present processed antigens to naïve T lymphocytes,
initiating an adaptive immune response.38 The number of
myeloid DCs in circulation progressively declines with age and
is accompanied by a decrease in circulating CD34+ HSCs and
an increase in monocytes,39 implying that the generation of
DCs is partially dysregulated in aged individuals. In addition,
the capacities of DCs to uptake and migrate to secondary lymph
nodes are impaired with age.40 
The reduction of antigen uptake can also affect the subsequent
function of dendritic cells in antigen processing and presenta-
tion, ultimately leading to changes in T cell-mediated immune
responses. Inflammaging in elderly individual can also
influence the activation and function of DCs, thereby affecting
both the innate and adaptive arms of the immune system. DCs
from elderly individuals also displayed a more mature
phenotype with reduced capacity to induce MHC class II
molecules and altered capacity to produce Th1 cytokines, such
as IL-12.40 Since proper functioning of DCs is essential for
optimal immune responses to infection and cancer, impairments
in DC function in aged individuals may compromise the
immune system’s ability to protect the host. 
4. Systemic Mediators of Immune Aging
4.1 Inflammaging 
Inflammatory responses are an essential component for host
defense against infectious pathogens. On the other hand, a
strong correlation of chronic inflammation with the
development or progression of long-term tissue damage,
cancer, autoimmune disorders, cardiovascular diseases,
atherosclerosis, neurodegeneration and higher mortality has
been documented.41 Cytokines, chemokines, growth factors
and lipid metabolites are the key regulators of immune cell
function and differentiation, and thus dysregulation of these
regulators is believed to be associated with various human
diseases. Age-associated systemic elevations in TNF-α, IL-6,
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PGE2 and IL-1β have been described as a subclinical
inflammatory status defined as inflammaging42 and are
attributed to lifelong exposure of the immune system to the
environment. Inflammaging in the elderly can contribute to
defects in the host immune system through the augmentation of
infection-related tissue damage. The increased levels of
systemic inflammatory cytokines might be caused by pre-
existing disease conditions in the elderly or by age-related
defects in the innate immune system. 
Recent studies of gene expression profiles from different age
groups showed that age is accompanied by a decline in first-line
defense mechanisms, with augmentation of the inflammation
process,36 supporting the concept of inflammaging. The clinical
significance of inflammaging has been demonstrated in a recent
study that reduction of the inflammatory milieu increased
lifespan in mice.43 Thus, the detrimental effects of chronic
inflammation on cardiovascular disease, age-associated muscle
loss, metabolic syndrome and other health issues of the elderly
are being realized.44 In line with this, enhanced anti-
inflammatory cytokines in the circulation of the elderly, such as
IL-10, or inflammatory modulating drugs, such as statins and
nonsteroidal anti-inflammatory drugs (NSAIDs), may be
beneficial for preventing these conditions.45 Although these
approaches cannot completely restore the altered immunity,
they are useful in attenuating some of the inflammaging-
associated disease progression. While heightened basal levels
of inflammation activity in elderly individuals might be a
survival disadvantage for infection, cancer or autoimmune
diseases, active biomedical or pharmacological modulation of
inflammaging may promote healthy aging. 
4.2 Advanced Glycation Endproducts (AGEs), TLRs
and Inflammation
Proper activation of innate immunity depends on non-specific
recognition of various pathogens by innate immunity receptors
such as TLRs and receptors for advanced glycation endproduct
(RAGE). TLRs are a set of germline-encoded pathogen-
associated molecular pattern (PAMP)-recognizing receptors that
mainly recognize conserved molecular patterns of exogenous
signals from microorganisms, whereas RAGE recognizes
ligands, such as HMGB1, which are danger signals that emanate
from endogenous tissue damage. Because TLR and RAGE
recognize both exogenous and endogenous danger signals and
alert the body to potential danger, they are collectively referred
to as alarmins.46 TLRs with broad ligand specificity trigger
innate immune responses by recognizing conserved elements of
molecular patterns in pathogens and activate antigen presenting
cells such as dendritic cells and macrophages, playing a crucial
role in the innate immune response.47 
At present, there are 11 known human TLRs and 13 murine
TLRs. Of these, 9 are well defined with analogous ligands in
humans and mice. TLRs exist as heterodimers or homodimers
and bind to pathogen-associated molecular patterns such as di/
triacylated lipopeptides, lipopolysaccharide (LPS) and
flagellin.47 The di/triacylated lipopeptides mainly interact with
TLR 1/2, whereas LPS and flagellin interact mainly with TLR 4/
4 and TLR 5/5, respectively.47 Activation of TLRs on
inflammatory cells results in the production of various pro-
inflammatory cytokines such as TNF-α, IL-6, macrophage
inflammatory protein 1-α (MIP-1α), and RANTES.47 TLRs are
important for activation of antigen presenting cells and therefore
play an important role in linking the innate immune response
with activation of the adaptive immune response.48,49 
Aging is associated with a decrease in TLR activity, which
may contribute to impaired innate immunity in the elderly. In a
study comparing an elderly population older than 65 years
(N=80) with young adults between 21-30 years of age (N=80),
there was a significant decrease in the response of monocytes to
TLR 1/2 agonist (Pam 3CSK4) in the elderly.28 Compared to
young individuals, there was a 50% decrease in the productions
of TNF-α and IL-6 in response to a TLR 1/2 agonist, which was
in part due to a 36% lower expression of TLR 1/2 on the surface
of monocytes in the elderly. Aging is associated with an
accumulation of injuries attributed to increased formation of
ROS, such as superoxide anions, hydroxyl radicals and
hydrogen peroxide. ROS-induced DNA damage results in
activations of poly(ADP-ribosyl) polymerase and poly(ADP-
ribosyl)ation of glyceraldehydes-3-phosphate dehydrogenase
(GA3PDH), resulting in nuclear translocation of GA3PDH and
ultimately its inhibition. The resulting accumulation of
upstream intermediates of the glycolytic pathway and
dihydroxyacetone phosphate (DHAP) results in increased
formation of advanced glycation endproducts such as
methylglyoxal, which act to promote formation of advanced
glycation endproducts (AGEs).50 
Administration of D-galactose to 5-month-old mice resulted
in modified AGEs and induced changes resembling accelerated
aging including immune aging and neurological impairment.
These changes were prevented by administration of an AGE
formation inhibitor (aminoguanindine).51,52 Thus, this model
suggests that AGE, at least partially, accounts for the aging in
the immune system. Interaction of AGEs with RAGE leads to
perturbation in diverse states of diseases, such as diabetes,
inflammation, autoimmune disease, cancer, cardiovascular
disease and neurodegenerative disease.53 RAGE is a type 1
membrane protein in the immunoglobulin superfamily and is a
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pattern recognizing receptor against diverse pathogens, playing
important roles in innate immunity but also interacting with
diverse endogenous ligands such as HMGB1, S100A12 as well
as AGE, resulting in chronic inflammation. This protein is
expressed abundantly in normal lung tissue and in macrophages
and at low levels in non-activated T cells, podocytes, Müller
cells of the retina neurons, glial cells vascular smooth muscle
cells and endothelial cells. However, in pathologic states,
expression in vascular smooth muscle cells and endothelial
cells is up-regulated.53 RAGE ligation is known to triggers a
series of diverse cellular signaling events, including activation
and nuclear translocation of NFκB, leading to up-regulation of
myriads of cytokines, cell adhesion molecules and ROS
generation, all of which promote inflammation and recruitment
of proinflammatory cells.53-55 Thus, increased accumulation of
AGEs with aging and subsequent increases in AGE-RAGE
interactions may be one of the mechanisms for increased age-
associated inflammation (inflammaging). In a study by Hallam
et al.56 which compared the vascular functions of elderly Fisher
rats (24-36 months) compared to those of young rats (4
months), there was a significant accumulation of methylglyoxal
and increased expression of RAGE in the aorta of elderly rats.
Administration of soluble RAGE resulted in significant
improvement of endothelial function of the aorta in the elderly
rats, demonstrating that age-associated vascular dysfunction
may be mediated in part by increased AGE-RAGE interac-
tion.56
Decreased expression and function of TLRs, along with
increased AGE-RAGE interactions in aging, may partly
explain inflammaging, the paradoxical finding of increased
inflammation and simultaneous immunocompromise. 
5. Immunorestorative Interventions in 
the Aged Population: Perspectives
There is accumulating experimental evidence suggesting that
innate and adaptive immunities are weakened with age, leading
to increased incidence and susceptibility to diseases (infection,
cancer,  autoimmune diseases,  cardiovascular and
neurodegenerative diseases). A number of different strategies
can be used to counteract the decline in immune function in the
elderly (Table 1).57,58 While there are a number of means to
intervene in immune aging including balanced nutrition and
exercise, there remains a strong need for specific, effective and
safe immune-restoring therapies for elderly individuals with
reduced immunity. 
Since immune aging is clearly associated with hematopoiesis,
it can, in theory, be reversed by improving the qualities of HSC
compartments. Administration of hematopoietic growth factors
or cytokines can modulate hematopoiesis to compensate for the
functional and numerical deficits of innate immunity. Indeed,
administration of M-CSF to aged mice partially restored
immunity against opportunistic infection.59 Animal models of
heterochronic parabiotic pairs of aged and young mice
demonstrated that young systemic factors rejuvenated old
hematopoietic compartments.60 Identification of factors that
have such critical influences on hematopoiesis and innate
immunity has great clinical implication. In a clinical setting, this
can be partly fulfilled through the collection of serum and HSCs
from young patients and the transplantation of long-term banked
Table 1. Strategies to restore immunosenescence in aged individuals.
Preventive or curative strategies to restore altered 
innate immunity
Examples; Mode of action
Hematopoietic growth factors or cytokines 
(systemic or local administration)
M-CSF; stimulate and correct hematopoiesis to compensate 
for the functional deficits of the cells of innate immunity, 
enhance the function of neutrophils and NK cells
Modulation of inflammaging through pharmacological or 
antibodies
Anti-TNF-α; reduce basal level of systemic inflammation
Modulation of AGE formation or inhibition of AGE-RAGE 
interaction
Prevent AGE-mediated accelerated aging processes, 
including immune aging
Hormonal or nutritional intervention DHEA, zinc supplements, vitamins and melatonin; enhance 
the functions of neutrophils and NK cells.
Local IGF-1 neutralization Anti-IGF-1; enhancement of hematopoietic activity in aged
bone marrow 
Autologous blood/plasma transfusion Autologous blood at a young age; replenish functionally 
competent immune cells of the innate and adaptive arms of 
the immune system
Hematopoietic stem cell therapy Autologous or allogeneic HSC transplantation to restore 
hematopoietic compartments and the immune system
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autologous HSCs and serum for restoration of immunity at an
advanced age. 
Correction of dysfunctional microenvironments or systemic
inflammaging via pharmacological means or through the use of
antibodies to inflammatory mediators may also contribute to
rejuvenation of the innate immune system. The finding that
blocking antibodies and soluble receptors for pro-inflammatory
cytokines, such as TNF-α, have notable therapeutic effects on
several autoimmune diseases61 supports the potential benefit of
this approach in age-associated chronic inflammation.
Inhibitors of AGE formation51 or AGE-RAGE interaction56 can
be administered to improve age-associated subclinical
inflammation. Hormonal/cytokine therapies may be useful for
the treatment of the age-associated decline. For example,
dehydroepiandrosterone (DHEA) supplements are known to
enhance the functions of neutrophils and NK cells.62 IGF-1 has
controversial effects on immune aging.63 Although a low level
of IGF-1 utilization is known to be associated with longevity in
a centenarian population,64 this cytokine increases the functions
of NK cells and macrophages.65 Furthermore, enhancement of
hematopoietic activity in aged bone marrow due to IGF-1
neutralization60 underlines the importance of this cytokine in
the regulation of stem cells. Although this cytokine approach is
attractive for immune rejuvenation, known toxic side effects
may limit their clinical application.
Autologous blood cell collection and cryopreservation at a
young age may be a unique and ideal source for restoring
immunity in the elderly,66 as it contains functionally competent
immune cells of the innate as well as adaptive arms of the
immune system. These cell sources have obvious advantages
over allogeneic sources because they are fully compatible to the
recipients with no concerns of rejection, disease transmission or
other transfusion-related adverse effects. Furthermore,
techniques for blood/bone marrow collection, in vitro cell
manipulation, long-term cryopreservation and transfusion have
greatly improved and have become routine procedures. Although
current data suggest that alterations in hematopoietic stem cell
compartments in the aged correlate with immune aging, it is not
clear whether replacing aged HSCs with young ones will restore
innate immunity, and more studies are still needed. 
The ideal therapeutics for restoration or rejuvenation of
defective immunity in the elderly should be easy to administer,
easy to produce or synthesize, and safe. Although rejuvenation
of an aging immune system to the levels of those in young
individuals may not be achievable, a modest enhancement in
immune function may be of clinical benefit. A better
understanding of immune aging is essential for the development
of new therapeutic strategies that ultimately lead to improve-
ments in the quality of life in the elderly population. 
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